Biologic monotherapy in the treatment of rheumatoid arthritis

Jacqueline Detert, Pascal Klaus Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) – preferabl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Detert J, Klaus P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/94ad9370a07342f293587bb13dcb7aa7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94ad9370a07342f293587bb13dcb7aa7
record_format	dspace
spelling	oai:doaj.org-article:94ad9370a07342f293587bb13dcb7aa72021-12-02T05:10:56ZBiologic monotherapy in the treatment of rheumatoid arthritis1177-5491https://doaj.org/article/94ad9370a07342f293587bb13dcb7aa72015-05-01T00:00:00Zhttp://www.dovepress.com/biologic-monotherapy-in-the-treatment-of-rheumatoid-arthritis-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Jacqueline Detert, Pascal Klaus Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) – preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is affected mainly by drug-induced intolerances (eg, MTX). Thus, the acceptance of the patient to treatment is often so inadequate that a discontinuation of the drug is necessary. In daily practice, approximately 30% of patients with biological therapy receive no concomitant DMARD according to the register data. Keywords: efficacy, safety, methotrexate, autoimmune diseaseDetert JKlaus PDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 35-43 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Detert J Klaus P Biologic monotherapy in the treatment of rheumatoid arthritis
description	Jacqueline Detert, Pascal Klaus Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) – preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is affected mainly by drug-induced intolerances (eg, MTX). Thus, the acceptance of the patient to treatment is often so inadequate that a discontinuation of the drug is necessary. In daily practice, approximately 30% of patients with biological therapy receive no concomitant DMARD according to the register data. Keywords: efficacy, safety, methotrexate, autoimmune disease
format	article
author	Detert J Klaus P
author_facet	Detert J Klaus P
author_sort	Detert J
title	Biologic monotherapy in the treatment of rheumatoid arthritis
title_short	Biologic monotherapy in the treatment of rheumatoid arthritis
title_full	Biologic monotherapy in the treatment of rheumatoid arthritis
title_fullStr	Biologic monotherapy in the treatment of rheumatoid arthritis
title_full_unstemmed	Biologic monotherapy in the treatment of rheumatoid arthritis
title_sort	biologic monotherapy in the treatment of rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/94ad9370a07342f293587bb13dcb7aa7
work_keys_str_mv	AT detertj biologicmonotherapyinthetreatmentofrheumatoidarthritis AT klausp biologicmonotherapyinthetreatmentofrheumatoidarthritis
_version_	1718400543977635840

Biologic monotherapy in the treatment of rheumatoid arthritis

Ejemplares similares